Stay updated with breaking news from Timothy Rolph. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Equities researchers at UBS Group assumed coverage on shares of Akero Therapeutics (NASDAQ:AKRO – Get Free Report) in a research note issued to investors on Monday, Marketbeat Ratings reports. The firm set a “buy” rating and a $83.00 price target on the stock. UBS Group’s price target would indicate a potential upside of 66.27% from […]
This edition of International People Moves details appointments at Arch Insurance, Canopius, and Willis Towers Watson (WTW). A summary of these new hires
Akero Therapeutics, Inc. (NASDAQ:AKRO – Get Rating) insider Timothy Rolph sold 509 shares of Akero Therapeutics stock in a transaction that occurred on Tuesday, June 13th. The shares were sold at an average price of $55.16, for a total transaction of $28,076.44. Following the completion of the transaction, the insider now directly owns 189,420 shares […]
Akero Therapeutics, Inc. (NASDAQ:AKRO – Get Rating) insider Timothy Rolph sold 509 shares of the business’s stock in a transaction on Tuesday, June 13th. The stock was sold at an average price of $55.16, for a total value of $28,076.44. Following the transaction, the insider now owns 189,420 shares in the company, valued at $10,448,407.20. […]
Martingale Asset Management L P lowered its position in Akero Therapeutics, Inc. (NASDAQ:AKRO – Get Rating) by 41.6% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 15,316 shares of the company’s stock after selling 10,895 shares during the period. […]